the eligibility criteria for inclusion in the study were as follows: * male and female hospitalized patients who have signed an informed consent. * aged between 18-85 years old. * rt-pcr confirmed covid-19. * fever (over 37.2 celsius degrees). * ct scan percentage area of lung involvement with ground-glass opacities \< 50 %. * respiratory rate \< 20-30 /min * spo2 ≥ 95%. the exclusion criteria were as follows: * oxygen support (ventilation and non-invasive) * uncompensated or exacerbated concomitant diseases or conditions that may complicate or make the patient's participation in the study impossible, or make it difficult to explain clinical findings. * any known intolerability to any of the study regimens' components. * patient's family or official relations with a member of staff of the clinical site. * patient's failure to assess his/her physical and/or emotional condition. * patient's failure to comply with the study requirements. * patient's refusal to participate in the study. * pregnancy or breastfeeding.

the eligibility criteria for inclusion in the study were as follows: * male and female hospitalized patients who have signed an informed consent. * aged between 18-85 years old. * rt-pcr confirmed covid-19. * fever (over 37.2 celsius degrees). * ct scan percentage area of lung involvement with ground-glass opacities \< 50 %. * respiratory rate \< 20-30 /min * spo2 ≥ 95%. the exclusion criteria were as follows: * oxygen support (ventilation and non-invasive) * uncompensated or exacerbated concomitant diseases or conditions that may complicate or make the patient's participation in the study impossible, or make it difficult to explain clinical findings. * any known intolerability to any of the study regimens' components. * patient's family or official relations with a member of staff of the clinical site. * patient's failure to assess his/her physical and/or emotional condition. * patient's failure to comply with the study requirements. * patient's refusal to participate in the study. * pregnancy or breastfeeding.

the eligibility criteria for inclusion in the study were as follows: male and female hospitalized patients who have signed an informed consent. aged between 18-85 years old. rt-pcr confirmed covid-19. fever (over 37.2 celsius degrees). ct scan percentage area of lung involvement with ground-glass opacities < 50 %. respiratory rate < 20-30 /min spo2 ≥ 95%. the exclusion criteria were as follows: oxygen support (ventilation and non-invasive) uncompensated or exacerbated concomitant diseases or conditions that may complicate or make the patient's participation in the study impossible, or make it difficult to explain clinical findings. any known intolerability to any of the study regimens' components. patient's family or official relations with a member of staff of the clinical site. patient's failure to assess his/her physical and/or emotional condition. patient's failure to comply with the study requirements. patient's refusal to participate in the study. pregnancy or breastfeeding.

the eligibility criteria for inclusion in the study were as follows: male and female hospitalized patients who have signed an informed consent. aged between 18-85 years old. rt-pcr confirmed covid-19. fever (over 37.2 celsius degrees). ct scan percentage area of lung involvement with ground-glass opacities < 50 %. respiratory rate < 20-30 /min spo2 ≥ 95%. the exclusion criteria were as follows: oxygen support (ventilation and non-invasive) uncompensated or exacerbated concomitant diseases or conditions that may complicate or make the patient's participation in the study impossible, or make it difficult to explain clinical findings. any known intolerability to any of the study regimens' components. patient's family or official relations with a member of staff of the clinical site. patient's failure to assess his/her physical and/or emotional condition. patient's failure to comply with the study requirements. patient's refusal to participate in the study. pregnancy or breastfeeding.

inclusion criteria: male or female adult aged ≥18 years at the time of enrollment. subjects with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection as defined below: mild (uncomplicated) illness: diagnosed with covid-19 by a standardized rt-pcr assay and mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise, headache, muscle pain, or malaise, but with no shortness of breath and no signs of a more serious lower airway disease and rr<20, hr <90, oxygen saturation (pulse oximetry) > 93% on room air. moderate illness: diagnosed with covid-19 by a standardized rt-pcr assay and in addition to symptoms above, more significant lower respiratory symptoms, including shortness of breath (at rest or with exertion) or signs of moderate pneumonia, including rr ≥ 20 but <30, hr ≥ 90 but less than 125, oxygen saturation (pulse oximetry) > 93% on room air and if available, lung infiltrates based on x-ray or ct scan < 50% present clinically normal resting 12-lead ecg at screening visit or, if abnormal, considered not clinically significant by the principal investigator. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. understands and agrees to comply with planned study procedures. women of childbearing potential must agree to use at least one medically accepted method of contraception (e.g., barrier contraceptives [condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or intrauterine devices) for the duration of the study.

inclusion criteria: male or female adult aged ≥18 years at the time of enrollment. subjects with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection as defined below: mild (uncomplicated) illness: diagnosed with covid-19 by a standardized rt-pcr assay and mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise, headache, muscle pain, or malaise, but with no shortness of breath and no signs of a more serious lower airway disease and rr<20, hr <90, oxygen saturation (pulse oximetry) > 93% on room air. moderate illness: diagnosed with covid-19 by a standardized rt-pcr assay and in addition to symptoms above, more significant lower respiratory symptoms, including shortness of breath (at rest or with exertion) or signs of moderate pneumonia, including rr ≥ 20 but <30, hr ≥ 90 but less than 125, oxygen saturation (pulse oximetry) > 93% on room air and if available, lung infiltrates based on x-ray or ct scan < 50% present clinically normal resting 12-lead ecg at screening visit or, if abnormal, considered not clinically significant by the principal investigator. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. understands and agrees to comply with planned study procedures. women of childbearing potential must agree to use at least one medically accepted method of contraception (e.g., barrier contraceptives [condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or intrauterine devices) for the duration of the study.

inclusion criteria: 1. male or female adult aged ≥18 years at the time of enrollment. 2. subjects with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection as defined below: mild (uncomplicated) illness: - diagnosed with covid-19 by a standardized rt-pcr assay and - mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise, headache, muscle pain, or malaise, but with no shortness of breath and - no signs of a more serious lower airway disease and - rr<20, hr <90, oxygen saturation (pulse oximetry) > 93% on room air. moderate illness: - diagnosed with covid-19 by a standardized rt-pcr assay and - in addition to symptoms above, more significant lower respiratory symptoms, including shortness of breath (at rest or with exertion) or - signs of moderate pneumonia, including rr ≥ 20 but <30, hr ≥ 90 but less than 125, oxygen saturation (pulse oximetry) > 93% on room air and - if available, lung infiltrates based on x-ray or ct scan < 50% present 3. clinically normal resting 12-lead ecg at screening visit or, if abnormal, considered not clinically significant by the principal investigator. 4. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 5. understands and agrees to comply with planned study procedures. 6. women of childbearing potential must agree to use at least one medically accepted method of contraception (e.g., barrier contraceptives [condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or intrauterine devices) for the duration of the study.

inclusion criteria: 1. male or female adult aged ≥18 years at the time of enrollment. 2. subjects with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection as defined below: mild (uncomplicated) illness: - diagnosed with covid-19 by a standardized rt-pcr assay and - mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise, headache, muscle pain, or malaise, but with no shortness of breath and - no signs of a more serious lower airway disease and - rr<20, hr <90, oxygen saturation (pulse oximetry) > 93% on room air. moderate illness: - diagnosed with covid-19 by a standardized rt-pcr assay and - in addition to symptoms above, more significant lower respiratory symptoms, including shortness of breath (at rest or with exertion) or - signs of moderate pneumonia, including rr ≥ 20 but <30, hr ≥ 90 but less than 125, oxygen saturation (pulse oximetry) > 93% on room air and - if available, lung infiltrates based on x-ray or ct scan < 50% present 3. clinically normal resting 12-lead ecg at screening visit or, if abnormal, considered not clinically significant by the principal investigator. 4. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 5. understands and agrees to comply with planned study procedures. 6. women of childbearing potential must agree to use at least one medically accepted method of contraception (e.g., barrier contraceptives [condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or intrauterine devices) for the duration of the study.